FDA Clears First 4-in-1 Home Test for RSV, Flu, and COVID Detection
ACON Laboratories has received FDA clearance for the first over-the-counter home test that simultaneously detects RSV, influenza A, influenza B, and COVID-19, representing a significant advancement in consumer respiratory health monitoring.
ACON Laboratories, Inc. has received 510(k) clearance from the U.S. Food & Drug Administration for its Flowflex® Plus RSV + Flu A/B + COVID Home Test, marking a significant milestone in consumer healthcare accessibility. This innovative product represents the first FDA-cleared 4-in-1 respiratory home test capable of detecting and differentiating between respiratory syncytial virus, influenza A, influenza B, and SARS-CoV-2 antigens from a single nasal swab sample.
The clearance of this multi-pathogen test addresses a critical need in respiratory health management, particularly during seasonal outbreaks when symptoms across these infections often overlap. The ability to distinguish between RSV, flu, and COVID-19 at home enables consumers to make more informed decisions about treatment and isolation protocols without requiring clinical visits. This development is especially important given that respiratory infections can present with similar symptoms but may require different management approaches and treatments.
Notably, this test breaks new ground as the first FDA-cleared respiratory home test authorized for children aged 6-23 months when administered by an adult using ACON's proprietary nasal swab guard. This pediatric authorization represents a major advancement in home healthcare for young children, who are particularly vulnerable to severe outcomes from respiratory infections. The domestic manufacturing of the test at ACON's San Diego facility ensures consistent supply and quality control for American consumers.
Michael Lynch, VP of Sales & Marketing at ACON, emphasized the product's significance for vulnerable populations, stating that the test will bring peace of mind to parents of young children, the elderly, immune-compromised individuals, and those in contact with at-risk groups. The simultaneous detection capability is particularly valuable for households with multiple family members experiencing respiratory symptoms, allowing for targeted care and reducing the spread of infections.
The Flowflex Plus RSV + Flu A/B + COVID Home Test will be available through major retailers later this year, with distribution information accessible at https://www.flowflexcovid.com. As the respiratory virus season approaches, this innovation in home testing technology represents a substantial step forward in empowering consumers to take control of their respiratory health management while reducing strain on healthcare systems.